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The BioBreeding rat develops a spontaneous syndrome resembling human
type I diabetes mellitus. Salient features include abrupt onset ofinsulin depend-
ent, ketosis-prone diabetes between 60-120 d of age (1); lymphocytic insulitis
with virtually complete destruction of pancreatic ,Q cells (2, 3); and genetic
predisposition and occurrence of hyperglycemia in the majority of inbred Bio-
Breeding/Worcester (BB/Wor)' animals (4).
Support for an immune pathogenesis ofBB/Wor diabetes is derived from the
following lines of evidence: lymphocytic insulitis before and during the acute
phase of hyperglycemia (1-3); ability to adoptively transfer diabetes with injec-
tions of Con-A stimulated diabetic spleen cells (5, 6); MHC-linked susceptibility
to diabetes (7); apparent presence ofantibodies against islet cell surface molecules
in diabetic and diabetes-prone animals (8); prevention of diabetes by neonatal
thymectomy and immune suppression (9-14); prevention ofdiabetes by immune
enhancement measures that correct the rats' immune incompetence (15-18).
The precise phenotypic identification of the effector cells that mediate final
destruction of the pancreatic # cells has not been accomplished. Although
lymphocytes and macrophages infiltrate the pancreatic islets, and la' macro-
phages are numerous (2, 19, 20), the functional role and specificity of these
inflammatory cells is uncertain, since animals protected from diabetes by most
immune-suppressive measures (9-11, 13) frequently show histologic evidence of
lymphocytic insulitis despite the presence of normal plasma glucose levels. The
questions raised by the latter morphologic observations encouraged us to design
experiments for the treatment of diabetes-prone BB/Wor rats using mAbs that
react with antigens expressed by rat lymphocyte subsets. Our experiments
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TABLE I
mAbs Used in This Study
Materials and Methods
contained two principal objectives: first, to determine whether injections of mAbs
would in fact be useful for the prevention of BB/Wor diabetes; second, if we
were successful in achieving our first objective, to identify the lymphocyte
subset(s) that mediate pancreatic ,# cell destruction .
We report here that (a) phenotypic OX19-reactive lymphocytes (all T cells)
and OX8-cells (cytotoxic/suppressor and NK cells) were selectively depleted
from adult BB/Wor rats by prolonged injections of tissue culture supernatants
(TCS) containing OX 19 or OX8 mAbs; (b) NK lytic activity was significantly
reduced in OX8-depleted animals; (c) rats treated with either OX8 or OX19
TCS were protected against the occurrence of diabetes . We conclude that the
subsets of rat lymphocytes that express OX8 and OX 19 surface antigens partic-
ipate in BB/Wor pancreatic (3 cell destruction.
Animals.
￿
Intact litters of diabetes-prone (DB-PRN) BB/Wor rats, 25-35 d ofage, were
obtained from the breeding colony maintained at the University of Massachusetts Medical
School. Animals in the 17-21st generation of brother X sister matings, with an expected
diabetes frequency of 40-80% were housed under specific pathogen-free (SPF) barrier
conditions wherein they received laboratory chow and water ad libitum. All animals were
tested for glycosuria three times weekly. Rats were considered diabetic if urine glucose
was 2-4+ with TesTape and plasma glucose values (Beckman Instruments, Fullerton, CA)
exceeded 200 mg/dl.
Antibodies. MRC OX6, OX8, OX17, OX19, W3/13, W3/25, OX35, OX38, and
OX52 mAb were produced by hybridoma cell lines obtained from Drs. A. F. Williams
and D. W. Mason, Oxford University (Oxford, United Kingdom) (21-23). 3JP producing
cells were received from Dr. Charles Janeway, Yale University (New Haven, CT). The
isotypes and reactivity of these mAbs are listed in Table I . The hybridoma cell lines were
cultured under standard tissue culture conditions, and the undiluted mAbs containing
TCS were stored at -20'C until the time for injection or use in the identification of
lymphocyte cell type by flow cytometry. Although the mAb concentrations in the TCS
were not quantified, each lot of TCS produced was tested by flow cytometry with normal
rat spleen cells to insure the presence ofsaturating concentrations of the specific antibody .
Fluoresceinated F(ab')z goat anti-mouse IgG (H and L chains), absorbed to remove
crossreactivity with rat IgG, was obtained from Cappel Laboratories, Cochranville, PA.
Hybridoma
number IgG class Specificity
W3/13 IgGI T cells, thymocytes, polymorphs, plasma cells, NK cells, brain
W3/25 (CD4) IgGI Helper/inducer cells (H/I), macrophages, thymocytes
OX35 (CD4) IgG2a H/I cells, macrophages, thymocytes. Does not compete with
W3/25 or OX38
OX38 (CD4) IgG2a H/I cells, macrophages, thymocytes. Competes with W3/25 but
not with OX35
OX8 (CD8) IgGI Cytotoxic/suppressor cells, NK, thymocytes
OX19 (CD5) IgGI T cells, thymocytes
OX52 IgGI T cells, thymocytes. Does not compete with OX19
OX6 IgGI la-A, nonpolymorphic
OX17 IgGI la-E, nonpolymorphic
3JP IgG2a Ia-A, nonpolymorphicLIKE ET AL.
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Animal Injections and Disposition.
￿
Litters were randomized into groups and injected
i.p. three times weekly with TCS containing the appropriate mAb, as follows: weeks 1
and 2, 1 .0 ml i.p. per rat; weeks 3 and 4, 1 .5 ml i.p. per rat; weeks 5 and 6, 2.0 ml i.p.
per rat; weeks 7-14, 2.5 ml i.p. per rat. Controls received injections of tissue culture
media (RPMI), or were uninjected. Representative nondiabetic animals were sacrificed
after 5, 9, and 14 wk of injections for the analysis ofsplenic lymphocytes by flow cytometry.
Diabetics were killed at detection of diabetes, and the remaining nondiabetics were killed
at 18 wk, i.e., 4 wk after the end of injections.
Morphologic Studies.
￿
At autopsy, pancreatic, and thyroid tissues were fixed in Bouin's
solution for routine light microscopic examination (by A. A. Like) of H and E-stained
paraffin sections without knowledge of the treatment group or physiologic status of the
animal. Pancreatic sections were reviewed for the presence of lymphocytic insulitis and
end-stage islets, which are the characteristic islet lesions of diabetic BB rats. Lymphocytic
insulitis is defined as the presence of lymphocytes surrounding and infiltrating the
pancreatic islets (1-3). The term end-stage islet is defined as an irregular cluster ofresidual
islet cells that persist after destruction of the insulin-synthesizing,6 cells. Thyroid sections
were examined for evidence of lymphocytic thyroiditis, defined as the presence of
lymphocytes infiltrating among and distorting the thyroid follicles (24).
Autoantibodies.
￿
Serum samples of untreated, OX8-, and OX 19-injected animals were
assayed for autoantibodies reacting with smooth muscle and thyroid colloid by indirect
immunofluorescence (25).
Separation and Flow Cytometry ofSplenic and Peripheral Blood Lymphocytes.
￿
Spleen cells
were dispersed in cold RPMI tissue culture medium containing 5% newborn calf serum
and 0.1 % azide, and passed through Nitex filters. Splenic red blood cells were lysed with
0.15 M NH4CI in Tris buffer, pH 7.4. Peripheral blood leukocytes were separated by
centrifugation of EDTA-treated whole blood in Wintrobe tubes, separation of the buffy
coat, and lysing of red blood cells with NH4CI. After counting (Coulter Electronics, Inc.,
Hileah, FL), 3-5 x 106 cell aliquots were subjected to a primary incubation with the
appropriate mAb in undiluted TCS. The secondary incubation used FITC-conjugated
F(ab')z goat anti-mouse IgG (Cappell Laboratories) at a working concentration of 20,ug/
ml. Normal rat serum (final concentration 10%) was added to reduce further the
crossreactivity to rat IgG. The labeled cells were then examined in a FAGS 440 Flow
Cytometer (Becton Dickinson Immunocytometry Systems, Mountain View, CA). For each
experiment, we analyzed 25,000 viable cells having the forward and 90° light scattering
characteristics of lymphocytes. For two-color fluorescence analysis, 4 x 106 peripheral
blood leucocytes ofanimals treated with OX8 or OX 19 TCS for 10-14 wk were incubated
with undiluted OX8 or OX52 TCS. The cells were then incubated with FITC-goat anti-
mouse IgG, washed, and incubated with medium containing 200 Ag/ml mouse IgG to
block remaining active sites on the goat anti-mouse IgG. The cells were then incubated
with biotinylated OX 19 (26). After washing, the cells were incubated with 20 til phycoer-
ythrin-avidin (Becton Dickinson Immunocytometry Systems) diluted with 30 fd of tissue
culture medium . The cells were then fixed with 0.5% paraformaldehyde and examined
with a FACS 440 flow cytometer. Data from the two-color fluorescence experiments were
displayed in contour plots.
Chromium-release Cytotoxicity Assay.
￿
Microcytotoxicity assays were carried out as de-
scribed (27). YAC-1, a cell line extremely sensitive to lysis mediated by NK cells (28), was
labelled with Na5'Cr (Amersham Corp., Arlington Heights, IL) for use as target cells.
Effector cells were splenic mononuclear cells. Three or more E/T ratios ranging from
200:1 to 3:1 were tested on microtiter plates with 104 target cells/well. Medium was
added to target cells for spontaneous lysis determinations, and 1 % NP-40 was added for
determination of 100% lysis. Assays were incubated for 4-6 h in a humidified 37°C, 5%
COZ in air incubator. Plates were centrifuged before harvest, and one-half of the super-
natant fluid collected for radioactive counting in a Beckman gamma 5500 counter,
(Beckman Instruments, Palo Alto, CA). The quadruplicate samples had standard devia-
tions of <5% of the mean. Spontaneous release in different assays ranged from 5 to 12%.1145
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TABLE II
Effects of mAb Injections on Splenic Lymphocyte Subsets
The data were derived from aglycosuric animals sacrificedafter 5, 9, and 14 wk ofTCS injections.
The splenic lymphocyte subsets were similar at each time point, and were therefore pooled.
* p < 0.05 for OX 19 treatment vs. all other groups. SNK and LSD with BFA. p < 0 .001 for OX 19
vs. all other groups (except W3/25). LSD with BFA.
$ p < 0 .05 for W3/25 injection vs. OX8 treatment. SNK and LSD with BFA.
§ p < 0.05 for OX8 treatment vs. all other groups. SNK and LSD with BFA. p < 0.01 for OX8
treatment vs. no injection and OX 19 injection LSD with BFA.
Percent specific 5 'Cr release = 100 x [(cpm test sample) - (cpm . medium control)]/[(cpm
NP-40 control) - (cpm medium control)].
Statistical Procedures.
￿
One-way analyses of variance were used to compare the effects
of the various treatment regimens on splenic and peripheral lymphocyte subsets. Individ-
ual pairs of groups were compared using a Student-Newman-Keuls (SNK) as well as a
Fisher's least significant difference (LSD) Test with a Bonferonni adjustment (BFA) to
compensate for additive type I errors. The effects of treatment on the frequency of
diabetes, insulitis, and thyroiditis were analyzed using Fisher's exact test with BFA.
Cytotoxicity data were analyzed using a student's t test. The effects of OX8 and OX19
treatment on autoantibody frequency were compared with the Fisher's exact test.
Results
Effects ofAntibody Injections on Lymphocyte Subsets.
￿
Splenic lymphocyte subsets
of uninjected diabetes-prone rats revealed the anticipated profound T lympho-
penia and reduced percentages of W3/25 and OX8 subsets (Table II) (26, 29-
31). OX6-staining B lymphocytes were reciprocally increased. Injections of TCS
containing OX 19 mAb significantly reduced the mean percentage of OX 19+
splenic lymphocytes. OX 19-injected animals, however, did not reveal significant
reductions of W3/13 + and W3/25+ cells, raising the possibility that OX19 mAb
injections may have resulted in clearance of splenic T lymphocytes as well as
modulation of OX 19 membrane antigens from surviving splenic T cells. Injec-
tions of TCS containing OX8 mAb selectively and significantly reduced the
percentage of OX8+ splenic lymphocytes, without a detectable effect on other
subsets . None of the TCS containing mAb against the helper/inducer T cells
and la' and B cell subsets showed measurable effects on splenic W3/25+ or other
lymphocyte subsets (Table II). Similarly, the RPMI-injected rats and animals
injected with 3JP mAb revealed no alterations in spleen cell subsets (data not
shown).
To evaluate the possibility that OX 19 TCS injections resulted in both a
reduction of T cell numbers as well as the modulation of specific antigens from
the target cell surface membranes, two-color flow cytometry analyses were
Injections n
Percentage (mean ±
ox 19 W3/13
SEM) of cells
W3/25
staining positively
OX8
with:
OX6
None 12 7.3±0.8 12.3±1 .3 7.2±0.9 7 .1±0 .8 59.2±5.8
ox 19 14 1 .9±0.3* 10.9± 1 .6 5.2±0.6* 6 .8± 1 .3 56.0±6.6
OX8 13 8.5±0.7 14.6±2.9 9.2±0.7 1 .3±0 .2§ 61 .9±5.2
W3/25 4 6.8±1 .0 22.5±5.8 9.0±1 .3 9.3±2 .4 67 .5±9.2
OX35 6 7.3±1 .5 10.4±1 .5 8.7±1 .6 6.8±1 .0 50 .1±6.9
OX38 7 7.9±0.5 12.1±1 .4 8.6±0.6 6.7±0 .9 65 .7±4.6
OX6 6 7.6±0.9 8.7±1 .1 8.3±1 .1 7 .0±0.4 72.7±4.0LIKE ET AL.
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TABLE III
Two-color Flow Cytometry ofPeripheral Blood Lymphocyte Subsets
* p < 0.05 for untreated vs. OX 19- or OX8-treated rats. SNK. p< 0.01 for untreatedvs. OX 19-or
0X8-treated rats. LSD with BFA.
p < 0.05 for OX19 vs. untreated and OX8 treated rats. SNK. p < 0.001 for OX19 vs. untreated
and OX8-treated rats. LSD with BFA.
§p < 0.05 for OX19-injected vs. untreated rats. SNK. p < 0.001 for OX19-injected vs. untreated
rats. LSD with BFA.
p < 0.05 for OX8-treated vs. untreatedand OX 19-treated rats. SNK and LSD with BFA.
performed to compare the frequency of PBL staining with the noncompeting
pan-Tcell mAbs OX52 and OX19. OX52 andOX19 react with distinct proteins
on the cell surface membranes of all rat peripheral T cells (21, 23). The data
contained in Table III and illustrated in Fig. 1 B indicate that all PBL ofuntreated
diabetes-prone rats stained after incubation with OX52 were also stained after a
secondary incubation with OX19. Table III and Fig. 1, C and D indicate that
PBL ofOX 19-treated animals revealedequivalent (virtually complete)reductions
in the numbers ofOX19' and OX52+ cells. These data suggest that modulation
of OX19 membrane antigen was not responsible for the reduced frequency of
OX19+ cells. Were antigen modulation a factor, one would expect disparate
numbers ofresidual OX52+ and OX19+ cells.
Since
￿
peripheral
￿
T
￿
cells
￿
(OX19+)
￿
are
￿
comprised
￿
of nonoverlapping
helper/inducer (W3/25+) and cytotoxic/suppressor (0X8+) subsets, the OX8-,
OX19' cells are equivalent to the helper/inducer subset (21, 26). Table III and
Fig.
￿
1 A
￿
confirm
￿
the
￿
virtual
￿
absence
￿
of classical
￿
thymus-derived
￿
cyto-
toxic/suppressor (0X8+, OX19+) cells among untreated diabetes-prone BB/Wor
rats (26). Table III and Fig. 1, A and C reveal that OX19 injections significantly
and profoundly reduced the frequency of circulating OX8-, 0X19+ (helper)
cells, but did not significantly alter OX8+ subsets. In contrast, OX8 treatment
resulted in a significant reduction of NK (0X8+, OX19-) cells. The frequency
of helper (0X8-, OX19+) cells was not significantly altered by OX8 treatments
(Fig. 1 E and Table III).
Effects of Antibody Treatment on Disease.
￿
Table IV illustrates the frequency of
diabetes among the several treatment groups. Injections of TCS containing
either OX19 or OX8 profoundly reduced the incidence of diabetes from 61 to
0 and 12%, respectively (p < 0.001). Treatment with TCS containing 0X17,
W3/25, or OX35 significantly reducedthe frequency ofdiabetes when compared
with uninjected controls, but marginally when compared with animals injected
with tissue culture media. When the Fisher's exact test stand-alone p values of
the several treatment groups were corrected for the likelihood ofspurious results
with a BFA, only the OX8- and OX19-injected animals evidenced significant
Percentage (mean ± SEM) of cells staining with:
Injections n OX8-/0X19-
(NK)
0X8-/OX19'
(helper/inducer)
OX8*/OX19+
(cytotoxic/
suppressor)
0X52+/OX19*
(Pan-T)
None 7 5.3 ± 1.1 6.2 ± 0.77 0.51 ± 0.06* 6.4 ± 0.82
OX 19 12 9.03 ± 1.2 1.08 ± 0.441 0.16 ± 0.043 0.82 ± 0.30
OX8 9 0.56 ± 0.40 7.79 ± 1 .1 0.21 ± 0.04 ND1150
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FIGURE 1.
￿
Contour plots of PBL stained with OXS or OX52 followed by FITC-goat anti-
mouse IgG, biotinylated OX 19 and phycoerythrin-avidin. (A) PBL from untreated rat reveal
9.9% OX8+, OX19-, 5.5% OXS-, OX 19+, and 0% OX8*, OX 19+. (B) PBL from untreated
rat show 0.4% OX52+, 0X19-, 0.6% OX52-, 0X19+, and 5.6% OX52+, 0X19+. (C) PBL
from OX 19-treated rat reveal 8.7% OX8+, OX 19-, 0.6% OX8-, OX 19+, and 0.1% OX8+,
OX19'. (D) PBL from OX 19-treated ratshow 1.8% OX52+, OX 19-, 0.8% OX52-, OX 19+,
and 0% OX52+, 0X19+. (E) PBL from OX8-treated rat show 0.3% OX8+, 0X19-, 13.1%
OX8-, OX 19+, and 0.3% OX8+, OX 19*.
protection against diabetes (p < 0.01) (Table IV). Injections with OX38, 0X6,
or 3JP did not protect against diabetes, even when the data were statistically
examined without BFA.
Another parameter of protection was revealed when the pancreatic islets of
the autopsied rats were examined histologically. The diabetic members of eachLIKE ET AL.
TABLE IV
Frequency ofDiabetes after mAb Injections
Injections
￿
Incidence of diabetes
￿
Significance*
None
￿
43/70 (61)$
￿
NS
RPMI 17/27(63)
￿
NS
p < 0.051
The data included in Tables IV and V arethe combined resultsof eight
separate experiments. 3 of 8 experiments included RPMI-injected rats
as controls, and 5 of 8 experiments included uninjected controls. After
correction of stand-alone p values with BFA, only OX8- and OX19-
injected rats were protectedagainst diabetes (p < 0.01).
* Fischer's exacttest.
$ Percent in parentheses.
§ Compared with uninjected control.
1 Compared with RPMI-injected control.
TABLE V
Frequency of Diabetes, Insulitis and Thyroiditis
Numbersin parentheses represent percent incidence.
* Frequency of insulitis and thyroiditis in the absence of hyperglycemia.
$p < 0.001 OX 19 treatment vs. all other groups.
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treatment group could not be differentiated : all revealed marked insulitis with
extensive loss of /3 cells and end-stage islets. Histologically, the islets of the
nondiabetic rats were not uniform. None of the 43 normoglycemic OX19-
treated rats, and 44 of 57 (77%) normoglycemic OX8-treated rats revealed
lymphocytic insulitis (Table V) . The frequency of insulitis among nondiabetic
animals of each of the other treatment groups tended to be greater than the
incidence of diabetes. The numbers of animals in these groups were relatively
small, and the frequencies of insulitis were not significantly different. A third
measure of protection became evident when the incidence of lymphocytic thy-
roiditis was evaluated among nondiabetic rats. Only the OX 19 treatment group
was protected against thyroiditis (Table V).
Injections Diabetes Insulitis* Thyroiditis
None 43/70(61) 10/18(45) 11/18(61)
RPMI 17/27(63) ND ND
OX 19 0/49(0) 0/43 (0)* 2/34 (6)$
OXS 11/90(12) 44/57(77) 26/42(62)
W3/25 12/35(34) 12/15(80) 10/14(71)
OX35 14/36(39) 13/22(59) 8/23(35)
OX38 11/20(55) 8/9(89) ND
OX6 28/56(50) 3/10(30) 6/12(50)
ox 19
OX8
W3/25
0/49(0)
11/90(12)
12/35(34)
p <
p <
p <
p <
0.001 1
0.0010
0.02§
0.051
OX35 14/36(39) p < 0.05§
OX38 11/20(55) NS
OX6 28/56(50) NS
3JP 10/16(63) NS
OX 17 7/22(32) p < 0.03$1152
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TABLE V I
Serum Autoantibodies after mAb Injections
Discussion
* An individual serum sample was considered autoantibody-positive if it
reacted with either or both thyroid colloidand smooth muscle.
# Intensity offluorescence of each sample wasevaluatedsemiquantitatively
(1-4+). Mean intensity (±SEM) was calculated from the positive sera.
§p < 0.01 forOX8 treatment vs. no injections.
~~ p < 0.001 for OX8 treatment vs. OX 19.
p < 0.03 for OX 19 treatment vs, no injections.
The incidence of diabetes, insulitis, and thyroiditis were the same among
animals killed after 14 wk, the last week of TCS injections, and after 18 wk, 4
wk after the end of mAb treatment (data not shown). A final parameter of
immunologic intervention was demonstrated when the sera of untreated, OX8-
and OX 19-injected animals were examined for anti-thyroid colloidand -smooth
muscle antibodies . While OX 19 TCS reduced the frequency of autoantibody-
positive sera from 60 to 9% (p < 0.03), OX8 injections appeared to increase
both the frequency and intensity of autoantibodies (Table VI).
OXS Depletion of NK Cells.
￿
The absence of the OX19+, OX8+ T cyto-
toxic/suppressor cell population in diabetes-prone BB/Wor rats, and the fact
that virtually all OX8+ cells in these animals are NK cells (26, 32) led us to
examine the effects of OX8 and OX 19 TCS injections on functional NK activity.
Splenocytes of untreated normoglycemic DB-PRN animals and nondiabetic rats
treated with OX8 or OX 19 TCS for 10-14 wk were tested against NK-sensitive
YAC-1 target cells in a "Cr-release assay. Splenic mononuclear leukocytes
isolated from untreated DB-PRN rats had high NK lytic activity, and mediated
30-50% killing of YAC-1 target cells at E/T ratios of 200:1 (Fig. 2, DB-PRN).
Splenic mononuclear leukocytes isolated from OX8-treated animals were dra-
matically reduced in NK lytic activity and mediated only 10-15% lysis of YAC-
1 target cells under similar conditions (Fig. 2, OX8-treated DB-PRN). DB-RES
W-line animals are inherently low in the proportion of NK cells and NK cell
function (33), and NK cell activity mediated by splenic cells isolated from the
OX8-treated DB-PRN animals was comparable to that mediated by cells isolated
from the DB-RES rats (Fig. 2). Under conditions wherein splenic effector cells
isolated from pooled and individual untreated DB-PRN rats in six different
experiments had a geometric mean lysis of 29%, splenic cells isolated from OX8-
treated rats had a geometric mean lysis of 11 %. The difference between the two
groups was highly significant (p < 0.001). In contrast, injections of OX 19 TCS
had no significant effect on NK cell activity (Fig. 3).
The results reported above indicate that chronic injections of TCS containing
mAb that bind to all rat T cells (OX19+) or to cytotoxic/suppressor and NK cells
Injections Autoantibodies* Intensity of
fluorescencet
None 6/10(60) 2.4 ± 0.5
OX8 12/13 (92)§"° 2.9 ± 0.2
OX19 1/11 (9)' 1.5LIKE ET AL.
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FIGURE 2.
￿
Titration of NK cell activity. Mononuclear leukocytes were isolated from spleens
of untreated DB-PRN and DB-RES rats or DB-PRN animals injected with OX8 mAb for 14
wk. Spleen cellsfrom each of two animals were pooled. Samples were taken for flow cytometry
and cytolytic activity. Killing was measured in a 5-h "Cr-release assay against YAC-1 target
cells. The percent specific s Cr release at different E/T ratios is shown. The percentage of
OX8*, OX 19- cells for each preparation was as follows. DB-PRN: 6.3 (O), 3.6 (A); DB-RES:
3.1 (O); OX8-treated DB-PRN: 1.0 (O), 0.2 (A), 0.2 (").
(OX8+) will achieve stable reductions of the respective lymphocyte subsets and
provide profound (OX8) or complete (OX19) protection against BB/Wor dia-
betes. Although it is unambiguous that OX8 injections selectively reduced only
the frequency of OX8+ cells (i.e., NK cells) in diabetes-prone BB/Wor rats, the
results of OX19 injections require further analysis. The splenic lymphocytes of
OX19-treated animals studied with the technique ofsingle-color flow cytometry
revealed (Table II) markedly reduced numbersofOX19+ cells, but onlymarginal
reductions of helper (W3/25+) and W3/13+ cells. In contrast, PBL of a subse-
quent group of OX19-treated animals studied by two-color flow cytometry
revealed profound reductions of both OX52+, OX19+ (pan-T) and OX8-,
OX19+ (helper) cells. Since theabsolute numberandstaining intensityofW3/25'
helper/inducer lymphocytes are markedly reduced in DB-PRN animals, these
cells are technically difficult to quantify with accuracy using single-color flow
cytometry. We have observed that this subset of T cells is more accurately
counted by two-color flow cytometry after sequential incubation with OX8 and
OX19, both of which result in staining of greater intensity. Furthermore, the
interpretation ofdata concerning W3/13+ and W3/25+ cells derived from spleen
cell suspensions may be complicated by the presence ofplasma cells and NK cells1154
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FIGURE 3.
￿
Specificity of OX8 treatments for depletion of NK cell activity. NK cell activity
mediated by spleen cells isolated from untreated DP-PRN, DP-RES, OX8-treated DP-PRN,
and OX19-treated DP-PRN rats was examined in 5-7-h "Cr-release assays against YAC-1
target cells. Results shown were obtained with cells isolated from individual animals in five
different experiments (O, 0, p, /, A) and cells pooled from two animals in one experiment
(A). The E/Tratio was the same for all samples tested on a given day, and were as follows: O,
50:1 ; ", 50:1; 0, 33 :1 ; ", 100:1; A, 50 :1; A, 100:1 . Bars represent geometric means. The
statistical significances of the differences between experimental groups, and untreated DB-
PRN were: DB-RES p < 0.001 ; OX8-treated DB-PRN p < 0.001 ; OX 19-treated DP-PRN, p
> 0.5.
that are W3/13+ (21), and by the presence of macrophages, which express
W3/25 antigens (22). The technique oftwo-colorflow cytometry usingperipheral
blood leukocytes is therefore a more precise method ofdelineating Tcell subsets
in DB-PRN rats. We are therefore convinced that the reduced numbers of
helper/inducer cells in OX19-treated rats illustrated in Fig. 1 and Table III are
correct, and that OX19 treatment of DB-PRN rats in fact reduced the number
of W3/25' T lymphocytes.
The results reported above also indicate that injections of OX8 profoundly
protected and injections of OX19 TCS completely protected against diabetes.
Furthermore, although a substantial number ofnondiabeticOX8-treated animals
showed signs oflymphocytic insulitis, this wasnotobserved after OX19 injections.
We interpret these results to indicate a role forboth NK cells and helper/inducer
cells in the pathogenesis of BB diabetes .
The evidence that OX8 TCS injections reduced OX8+ cell numbers is sup-
ported by the in vitro NK assays. The reduction of phenotypic NK cells (OX8+,
OX19- by flow cytometry) (Table 111) correlated with a significant reduction in
the lysis ofYAC-1 cells in vitro (Figs. 2 and 3).
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The evidence indicating that NK cells contribute to the induction of diabetes
in the DB-PRN rat is now very persuasive. Both NK cell numbers and activity
are elevated on a per-cell basis in untreated DB-PRN as compared to DP-RES
rats (Fig. 2) (33). Data reported previously (19) indicate that 0X8+ cells are
localized at the site ofthe insulitis lesion in the BB/Wor rat. The data presented
here indicate that injections of OX8 mAb prevented diabetes and also resulted
in the clearing of 0X8+ cells from the spleen (Table II) and blood (Table III).
Since virtually all ofthe 0X8+ cells in DB-PRN rats belong to the NK cell subset
(26), and since OX8 injections both prevented diabetes and depleted NK cell
activity (Figs. 2 and 3), we believe that NK cells contribute to the mechanism of
(3 cell destruction. Although we can not exclude the possibility that another
0X8'}, 0X19- subset is (also) involved, this does not appear likely, since all
0X8+ cells in the DP-PRN rat are also brightly stained with a second NK cell
marker, AGMI (33).
Although OX19 injections protected against diabetes, they did not reduce the
number of NK cells or NK cell-mediated lysis of YAC-1 cells. Therefore NK
cells cannot be solely responsible for BB/Wor diabetes. It is reasonable therefore
to suggest that the helper/inducer cell subset is required for continued (lympho-
kine) stimulation of NK cell activity and/or the stimulation of B lymphocyte
synthesis of islet cell-surface antibodies, which may precede the temporal onset
ofdiabetes in the BB rat (8). Indirect support for the latter possibility is derived
from the evidence that autoantibodies directed against smooth muscle and
thyroid colloid were significantly reduced in OX19-injected rats (Table IV).
An alternate explanation for the reduction ofautoantibody synthesis in OX19-
treated rats is suggested by the reported (34) presence of a small subset of B
lymphocytes that bear the Ly-1 phenotype and are capable of synthesizing
autoantibodies in normal and immunodeficient mice. OX19 is thought to be the
analog ofmurine Ly-1 in the rat. To date, no such 0X19+ B cell subset has been
described. If, however, a comparable OX19+ B cell subset exists in the immu-
nodeficient BB/Wor rat, it is possible that the protective effects of OX19
treatment could be due in part to a direct effect on these B lymphocytes.
Injections ofTCS containing mAb that bind selectively to helper/inducer cells
(W3/25, 0X35, and 0X38) and to cells with class II (Ia) surface membrane
antigens (0X6, 3JP, and OX 17) did not reduce the percentages ofhelper or Ia+
splenic cell subsets. This was noted even after injections of mAb of the IgG2a
class (0X35, 0X38, and 3JP). The results reported above indicate that marginal
reductions in the frequency of diabetes were realized in W3/25- and 0X35
TCS-treated animals without reduced helper cell numbers. Furthermore, nor-
moglycemic recipients of anti-helper/inducer cell mAb did not reveal reduced
frequencies of insulitis. It is not known whether prolonged injections of larger
quantities ofmAb wouldhavereducedthe numberofW3/25+cellsand protected
more profoundly against diabetes (and insulitis). Injections of 6 mg of W3/25
ascites mAb to each of 10 diabetes-prone rats over a 3-wk interval neither
reduced splenic W3/25+ cells nor prevented diabetes (data not illustrated).
Brostoffand Mason (35) have reported the reduction in duration and amelio-
ration ofseverity ofexperimental allergic encephalomyelitis (EAE) in Lewis rats
after injections of milligram quantities of W3/25 without associated reductions1156
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of circulating T helper cells. Those workers speculated that the injected mAb
might impair helper cell function without cell loss. In confirmation of Brostoff's
observations was the report that injections of anti-helper cell (L3T4) mAb
prevented and ameliorated EAE in mice (36). Anti-L3T4 mAb also reduced the
severity of the autoimmune syndrome in NZB/NZW F, mice (37). In both groups
of mouse experiments, mAb treatment reduced circulating L3T4 cells.
The marginal protection against diabetes that followed injections of OX 17
(IaE) but not OX6 or 3JP (IaA) confirms the published report of Boitard, et al.
(38). Those investigators reported that injections of purified anti-IaE mAb
provided marginal protection against BB/Wor diabetes and lymphocytic thyroid-
itis, when considered individually. Protection, however, reached statistical signif-
icance only when the frequency of diabetes and thyroiditis were combined.
Boitard et al. did not report the effects of their treatments on lymphocyte subsets.
Finally, we note with interest that there was an unanticipated relationship
between the IgG class of the injected mAb and the reduction of T cell subsets.
Hence, OX8 and OX 19, both IgG1 isotypes, induced profound reductions of
PBL and splenocyte subsets, and protected against diabetes. OX35, OX38, and
3JP are all IgG2a isotypes, and in the quantities injected did not reduce the
number of their respective subsets. This contrasts with the report of Cobbold et
al. (39), wherein IgG2B but not IgGI mAb was responsible for in vivo helper T
cell elimination in mice.
Summary
Diabetes-prone BioBreeding/Worcester (BB/Wor) rats received thrice weekly
injections of mAb against antigens expressed on the surfaceof all T cells (OX19),
cytotoxic/suppressor, and NK cells (OX8), helper/inducer cells (W3/25, OX35,
OX38), and Ia+ cells(OX6, 3JP, OX 17). Treatmentwith OX8 or OX 19 achieved
stable reductions of splenic and peripheral blood NK cells and helper/inducer T
lymphocytes, respectively, and protected against diabetes. OX 19 injections also
prevented lymphocytic insulitis, thyroiditis, and the synthesis of autoantibodies
to thyroid colloid and smooth muscle antigens. OX8 injections reduced splenic
NK-mediated YAC-1 cell lysis, but did not prevent insulitis, thyroiditis, or
autoantibody synthesis. Injections of mAb specific for antigens on the surface of
helper/inducer cells, and for cells expressing IaE antigens provided marginal
protection against diabetes without reductions of phenotypic subsets. These
findings suggest that pancreatic a cell destruction in the spontaneously diabetic
BB/Wor rat is mediated by the combined action of NK and helper/inducer cells.
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